NewsBenzingaMorgan Stanley behält die Einstufung „Overweight“ für BeOne Medicines bei und erhöht das Kursziel auf 476 US-Dollar Morgan Stanley behält die Einstufung „Overweight“ für BeOne Medicines bei und erhöht das Kursziel auf 476 US-Dollar Benzinga 2026.11.13 17:58 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target If You Invested $1000 In Ulta Beauty Stock 15 Years Ago, You Would Have This Much Today